Millrose Properties enters the final week of September with an intriguing split personality: a buy-rated stock with 29% upside to analyst targets that has nonetheless shed 5.5% over the past month, while a cluster of insiders quietly accumulate at current levels.
The most distinctive feature of this setup is the options market's tilt toward calls. The put/call ratio has dropped to 0.38, running roughly 1.6 standard deviations below its 20-day average of 0.40 — the most bullish lean it has shown in months, and close to the 52-week low of 0.30. That suggests options participants are positioned for upside even as the stock drifts lower on a price basis, a divergence worth tracking.
Short interest gives little away. Bears hold roughly 4.8% of the free float — a middling level that has moved less than 0.5% on the week and remains well off any extreme. The borrow market is loose: availability runs near 1,900%, meaning shares to lend far exceed demand, and the cost to borrow is a negligible 0.44%. The short score of 43.7 is broadly flat over the past two weeks, offering no signal of building conviction from either side. Positioning looks passive rather than charged.
Where the story gets more interesting is in the insider register. Two directors — Matthew Gorson and Carlos Migoya — made open-market purchases in early August, both without 10b5-1 plans, at prices of $28.80 and $29.18 respectively. The COO also bought in May at $26.60. Collectively, insiders netted over $294,000 in open-market purchases over the past 90 days. These are modest in dollar terms, but they are discretionary and they cluster near current prices — a point of contrast with the broader price weakness. The activist register adds structural context: Stuart Miller and LMM Family Corp filed Schedule 13Ds in February 2025, together declaring stakes above 13% combined. Lennar, which spun Millrose out, has since reduced its position dramatically per a December 2025 13D/A amendment. BlackRock has meanwhile grown its stake to 13.8% of shares, per its July 2026 filing. As always with 13D/G disclosures, positions are as-last-filed and holders can exit below 5% without notice.
The Street remains constructive, if quietly so. All five analysts covering MRP rate it a buy, with a mean price target around $37 — implying roughly 29% upside from the $28.73 close. Note that the most recent analyst changes in the data are from late October 2025, so these targets are somewhat dated relative to today's price. The analyst recommendation differential factor scores in the 95th percentile, the highest reading across all factor categories, underscoring that relative to peers the Street consensus is unusually one-sided in favour of the stock. Forward EPS growth scores in the 81st percentile, while valuation at a P/E near 9x and price-to-book below 0.82 keeps the value case intact. The dividend yield factor scores in the 76th percentile, consistent with the roughly 11% DPS-to-price ratio implied by the valuation data. The single available earnings reaction — a 2.4% gain the day after the August 2026 print, extending to 3.8% over five days — offers a thin but positive post-results pattern, contrasted with a sharp 10.6% single-day drop after the May 2026 result. With no next earnings date confirmed, the binary risk of that May episode is a background consideration rather than an imminent one.
Closest correlated peers also drifted lower on the week: FCPT fell 4.5% and CUBE dropped 3.4%, suggesting the weakness in MRP is at least partly sector-wide rather than stock-specific. The degree to which the stock can stabilise and recapture its August levels — while insiders continue adding and options players lean toward calls — is the central tension to watch heading into October.
See the live data behind this article on ORTEX.
Open MRP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
